AR049962A1 - Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina - Google Patents
Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroinaInfo
- Publication number
- AR049962A1 AR049962A1 ARP050102788A ARP050102788A AR049962A1 AR 049962 A1 AR049962 A1 AR 049962A1 AR P050102788 A ARP050102788 A AR P050102788A AR P050102788 A ARP050102788 A AR P050102788A AR 049962 A1 AR049962 A1 AR 049962A1
- Authority
- AR
- Argentina
- Prior art keywords
- morphine
- preparation
- tfcs
- edc
- revealed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]
Abstract
Se revela el diseno estructural, métodos de preparacion y composicion química de dos formulaciones estructurales de vacunas bivalentes contra la adiccion a morfina-heroína (morfina-6-hemiscuccinil-EDC-TFCS-toxoide tetánico y 3-O-carboximetlmorfina- EDC-TFCS-toxoide tetánico), adecuados para su empleo en la vacunacion en el humano, los cuales son capaces de inducir la síntesis de anticuerpos policlonales contra este opiáceo adictivo y contra su análogo estructural la heroína, a través de su administracion repetida in vivo, en un esquema de vacunacion activa en estudios de fase preclínica en el modelo animal del roedor. También se revela el paradigma de vacunacion activa con estos inmunogenos, los cuales son capaces de inducir una respuesta inmunologica humoral de altos títulos de anticuerpos específicos séricos consolidada con memoria a largo plazo contra estas dos drogas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04006617A MXPA04006617A (es) | 2004-07-07 | 2004-07-07 | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049962A1 true AR049962A1 (es) | 2006-09-20 |
Family
ID=35431510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102788A AR049962A1 (es) | 2004-07-07 | 2005-07-05 | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina |
Country Status (15)
Country | Link |
---|---|
US (4) | US8008457B2 (es) |
EP (1) | EP1767221B1 (es) |
AR (1) | AR049962A1 (es) |
BR (1) | BRPI0513024A (es) |
CA (1) | CA2573042C (es) |
CU (1) | CU23917B1 (es) |
CY (1) | CY1114673T1 (es) |
DK (1) | DK1767221T3 (es) |
ES (1) | ES2435769T3 (es) |
MX (1) | MXPA04006617A (es) |
PE (1) | PE20060377A1 (es) |
PL (1) | PL1767221T3 (es) |
PT (1) | PT1767221E (es) |
SI (1) | SI1767221T1 (es) |
WO (1) | WO2006004390A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
US8170546B2 (en) | 2006-03-22 | 2012-05-01 | Broadcom Corporation | Client device characterization of other client device transmissions and reporting of signal qualities to access point(s) |
EP1982729A1 (en) * | 2007-04-20 | 2008-10-22 | Cytos Biotechnology AG | Vaccination Regimen for B-Cell Vaccines |
WO2011041483A2 (en) * | 2009-09-30 | 2011-04-07 | Toxcure, Inc. | Use of botulinum neurotoxin to treat substance addictions |
CN102002049B (zh) * | 2010-10-12 | 2013-01-02 | 北京大学 | 一种抗原及其制备方法与应用 |
CN102539764A (zh) * | 2010-12-27 | 2012-07-04 | 北京库尔科技有限公司 | 盐酸哌替啶检测试剂盒及其制备方法 |
EP2717057A1 (en) * | 2012-10-04 | 2014-04-09 | Cisbio Bioassays | Morphine-6-glucuronide derivatives, immunogens and immunoassay |
RU2526807C2 (ru) * | 2012-11-28 | 2014-08-27 | Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА" | Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ |
EP2970320B1 (en) | 2013-03-15 | 2020-10-28 | Johnson Matthey Public Limited Company | Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain |
US10262505B1 (en) * | 2013-12-03 | 2019-04-16 | Ca, Inc. | Anti-skimming solution |
WO2017127390A1 (en) | 2016-01-21 | 2017-07-27 | The Scripps Research Institute | Synthetic opioid vaccine |
WO2019094528A1 (en) | 2017-11-09 | 2019-05-16 | The Scripps Research Institute | An improved heroin vaccine |
WO2020012245A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Thienothiophene-naltrexone prodrugs for long-acting injectable compositions |
WO2020012248A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Novel naphthylenyl compounds for long-acting injectable compositions and related methods |
WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
RU2703494C1 (ru) * | 2018-11-12 | 2019-10-18 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Моноклональное антитело 6g1 к производным морфина |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH678394A5 (es) | 1990-08-22 | 1991-09-13 | Cerny Erich H | |
US6210677B1 (en) * | 1993-01-29 | 2001-04-03 | Robert C. Bohannon | Method to reduce the physiologic effects of drugs on mammals |
US5876727A (en) * | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
DE69637089T2 (de) | 1995-03-31 | 2008-01-17 | Xenova Research Ltd., Slough | Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie |
US20020032316A1 (en) * | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
CN1069544C (zh) | 1998-04-24 | 2001-08-15 | 昆明市生物技术工程研究中心 | 人用阿片类毒品戒毒疫苗 |
AU2004215125B2 (en) * | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
-
2004
- 2004-07-07 MX MXPA04006617A patent/MXPA04006617A/es active IP Right Grant
-
2005
- 2005-07-05 PE PE2005000780A patent/PE20060377A1/es active IP Right Grant
- 2005-07-05 PT PT57619173T patent/PT1767221E/pt unknown
- 2005-07-05 CA CA2573042A patent/CA2573042C/en active Active
- 2005-07-05 AR ARP050102788A patent/AR049962A1/es not_active Application Discontinuation
- 2005-07-05 US US11/632,085 patent/US8008457B2/en not_active Expired - Fee Related
- 2005-07-05 PL PL05761917T patent/PL1767221T3/pl unknown
- 2005-07-05 ES ES05761917T patent/ES2435769T3/es active Active
- 2005-07-05 SI SI200531802T patent/SI1767221T1/sl unknown
- 2005-07-05 EP EP05761917.3A patent/EP1767221B1/en active Active
- 2005-07-05 DK DK05761917.3T patent/DK1767221T3/da active
- 2005-07-05 BR BRPI0513024-7A patent/BRPI0513024A/pt not_active Application Discontinuation
- 2005-07-05 WO PCT/MX2005/000049 patent/WO2006004390A2/es active Application Filing
-
2007
- 2007-01-05 CU CU2007000002A patent/CU23917B1/es active IP Right Grant
-
2011
- 2011-07-14 US US13/182,634 patent/US8357375B2/en active Active
-
2012
- 2012-12-10 US US13/709,507 patent/US8916170B2/en active Active
-
2013
- 2013-11-20 CY CY20131101023T patent/CY1114673T1/el unknown
-
2014
- 2014-11-06 US US14/535,007 patent/US20150064212A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SI1767221T1 (sl) | 2014-01-31 |
CA2573042C (en) | 2013-01-15 |
US20150064212A1 (en) | 2015-03-05 |
US20080241183A1 (en) | 2008-10-02 |
EP1767221B1 (en) | 2013-08-21 |
BRPI0513024A (pt) | 2008-04-22 |
EP1767221A2 (en) | 2007-03-28 |
US20130236478A1 (en) | 2013-09-12 |
US20110318381A1 (en) | 2011-12-29 |
US8357375B2 (en) | 2013-01-22 |
DK1767221T3 (da) | 2013-11-25 |
PL1767221T3 (pl) | 2014-02-28 |
CY1114673T1 (el) | 2016-10-05 |
WO2006004390A2 (es) | 2006-01-12 |
PE20060377A1 (es) | 2006-05-05 |
PT1767221E (pt) | 2013-11-27 |
MXPA04006617A (es) | 2006-01-12 |
US8008457B2 (en) | 2011-08-30 |
CU23917B1 (es) | 2013-07-31 |
CA2573042A1 (en) | 2006-01-12 |
ES2435769T3 (es) | 2013-12-23 |
WO2006004390A3 (es) | 2006-09-21 |
CU20070002A7 (es) | 2009-09-08 |
US8916170B2 (en) | 2014-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049962A1 (es) | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina | |
Qiu et al. | DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN | |
Tan et al. | Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants | |
Zeng et al. | In vivo expansion of melanoma-specific T cells using microneedle arrays coated with immune-polyelectrolyte multilayers | |
Naito et al. | Antigen-loaded dissolving microneedle array as a novel tool for percutaneous vaccination | |
Selmi et al. | Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice | |
Kaurav et al. | Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage | |
CN103961701B (zh) | 疫苗组合物 | |
McCormick et al. | Chemical conjugate TMV− peptide bivalent fusion vaccines improve cellular immunity and tumor protection | |
Levast et al. | Vaccine potentiation by combination adjuvants | |
NO20015073L (no) | Vaksiner | |
Scheiblhofer et al. | Skin vaccination via fractional infrared laser ablation-Optimization of laser-parameters and adjuvantation | |
NO20021431L (no) | Intranasal influensavirus vaksine | |
Guo et al. | Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays | |
WO2008057235A3 (en) | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | |
WO2007022151A3 (en) | Immunization of avians by administration of non-replicating vectored vaccines | |
JP2012021028A5 (es) | ||
CN105920599A (zh) | 以阳离子脂质体dotap为佐剂的疫苗及其制备方法 | |
ES2702386T3 (es) | Modelos animales novedosos para evaluar compuestos farmacéuticos | |
ES2565578T3 (es) | Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal | |
Ungaro et al. | VLPs and particle strategies for cancer vaccines | |
ES2609839T3 (es) | Método de vacunación | |
Kuwentrai et al. | Induction of humoral and cellular immunity by intradermal delivery of SARS-CoV-2 nucleocapsid protein using dissolvable microneedles | |
Chen et al. | Maximizing TLR9 activation in cancer immunotherapy with dual-adjuvanted spherical nucleic acids | |
DE60136928D1 (de) | Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |